Brief report on a phase I/IIa study to assess the safety, tolerability, and immune response of AGMG0201 in patients with essential hypertension
Open Access
- 17 October 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Hypertension Research
- Vol. 45 (1), 61-65
- https://doi.org/10.1038/s41440-021-00755-6
Abstract
We have been developing an angiotensin II vaccine for hypertension. We conducted a placebo-controlled dose escalation study to investigate the safety, tolerability, and immunological responses of this angiotensin II vaccine (AGMG0201). AGMG0201 was administered to participants with mild to moderate hypertension between 18 and 79 years of age. Twelve patients each were enrolled in the low-dose and high-dose groups. Within each group, subjects were randomly assigned to receive either the active study drug or a placebo at a ratio of 3:1. Each participant received a single intramuscular injection, followed by a second injection 30 days later, and was monitored for 360 days after the second dose. The results showed that most treatment-related adverse events were classified as mild or moderate in severity, including pain and erythema at the injection site. Anti-angiotensin II antibodies were observed in the AGMG0201 patients, especially in the high-dose group. Overall, AGMG0201 was well tolerated.Keywords
This publication has 10 references indexed in Scilit:
- Vaccine Development against the Renin-Angiotensin System for the Treatment of HypertensionInternational Journal of Hypertension, 2019
- The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)Hypertension Research, 2019
- Angiotensin II Peptide Vaccine Protects Ischemic Brain Through Reducing Oxidative StressStroke, 2017
- A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarctionScientific Reports, 2017
- Long-Term Reduction of High Blood Pressure by Angiotensin II DNA Vaccine in Spontaneously Hypertensive RatsHypertension, 2015
- Decrease in Blood Pressure and Regression of Cardiovascular Complications by Angiotensin II Vaccine in MicePLOS ONE, 2013
- Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa studyThe Lancet, 2008
- A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicityJournal of Hypertension, 2007
- Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjectsClinical Science, 2004
- Evaluation of two carrier protein–angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in manBritish Journal of Clinical Pharmacology, 2003